中文摘要：

目的探讨六味补气胶囊对肺气虚型慢性阻塞性肺疾病（chronic obstructive pulmonary disease,COPD）稳定期患者生活质量和肺功能的影响。方法选择80例COPD稳定期肺气虚证患者,随机分为治疗组和对照组,每组40例。对照组和治疗组均给予常规治疗,治疗组在常规治疗的基础上给予六味补气胶囊口服。在治疗前后采用圣乔治呼吸问卷分别对两组患者的生活质量进行测评,并检测肺功能。结果治疗后对照组和治疗组分别脱落2、3例。治疗前后两组肺活量和第一秒用力肺活量（forced expiratory volume in onesecond,FEV1）比较,以及两组治疗后肺活量和FEV1比较,差异均无统计学意义（P〉0.05）。治疗后两组圣乔治呼吸问卷3个维度（呼吸症状、活动受限和疾病影响）评分显著低于治疗前（P〈0.01）,治疗组圣乔治呼吸问卷4个维度（呼吸症状、活动受限、疾病影响和生活质量）的改善明显优于对照组（P〈0.01）。结论六味补气胶囊干预肺气虚型COPD稳定期患者,能够减缓患者肺功能下降,提高生活质量。

英文摘要：

Objective To explore the effects of Liuwei Buqi（LWBQ） Capsules,a traditional Chinese prescription,on quality of life（QOL） and lung function in patients with stable phase chronic obstructive pulmonary disease（COPD） complicated with lung-qi deficiency syndrome.Methods Eighty patients with stable phase COPD complicated with lung-qi deficiency were randomized into treatment group and control group.The patients in the two groups were given conventional treatments;additionally,patients in the treatment group were treated with LWBQ Capsules.Before and after treatment,the patients＇ QOL of the two groups were evaluated using St George＇s Respiratory Questionnaire（SGRQ）,and the lung function was also detected.Results After treatment,there were two and three patients lost to follow-up in the control group and the treatment group,respectively.There were no significant differences in lung capacity and forced expiratory volume in one second（FEV1） between pretreatment and posttreatment,and between the control group and the treatment group（P0.05）.As compared with those before treatment,the scores of three dimensions（including respiratory symptoms,restricted movement,and disease＇s influence） of SGRQ were significantly decreased in the two groups after treatment（P0.01）;and the improvement of the four dimensions（including respiratory symptoms,restricted movement,disease＇s influence,and QOL） of SGRQ in the treatment group was superior to that in the control group（P0.01）.Conclusion Liuwei Buqi Capsules can slow down the decline of pulmonary function,and improve the QOL in patients with stable phase COPD complicated with lung-qi deficiency syndrome.